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Objectives: We report on outcomes after 7 years of a community-based antiretroviral
therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to
correct for mortality under-ascertainment.
Design: This is an observational cohort study.
Methods: Since inception,patient-level clinical data have been prospectively captured
on-site into an electronic patient information system. Patients with available civil
identiﬁcation numbers who were lost to follow-up were matched with the national
deathregistrytoascertaintheirvitalstatus.Correctedmortalityestimatesweightedthese
patients to represent all patients lost to follow-up. CD4 cell count outcomes were
reported conditioned on continuous virological suppression.
Results: Seven thousand, three hundred and twenty-three treatment-naive adults (68%
women) started ART between 2001 and 2007, with annual enrolment increasing from
80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months,
32.8% had died. Corrected mortality was 20.9% at 5 years (95% conﬁdence interval
17.9–24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell
count at enrolment increased from 43cells/ml in 2001 to 131cells/ml in 2006). Patients
who remained virologically suppressed continued to gain CD4 cells at 5 years (median
22cells/ml per 6 months). By 5 years, 14.0% of patients had failed virologically and
12.2% had been switched to second-line therapy.
Conclusion: At a time of considerable debate about future global funding of ART
programmes in resource-poor settings, this study has demonstrated substantial and
durable clinical beneﬁts for those able to access ART throughout this period, in spite of
increasing loss to follow-up.  2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
AIDS 2010, 24:563–572
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Introduction
Less than 10 years ago, opinions were divided as to
the feasibility of providing antiretroviral therapy
(ART) in those countries, mostly in Africa, in which
the majority of people living with HIV reside [1,2].
Since then, a number of African ART programmes
have demonstrated excellent adherence and clinical
outcomes for the ﬁrst wave of patients accessing care
[3–8].
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The focus of attention is now shifting from feasibility to
sustainability.Littleisknownabouteither thelonger term
outcomes on ART in these settings or whether the early
outcomes have been sustained for patients accessing care
more recently. In particular, the true outcomes of patients
who are lost to follow-up are hardly known outside of
study settings [7,9].
One of the ﬁrst programmes that demonstrated the
feasibilityofARTinSouthernAfricawastheKhayelitsha
ART programme [3], established in 2001 by Me ´decins
Sans Frontie `res and the provincial government of
the Western Cape, South Africa. Early outcomes from
the Khayelitsha programme helped to establish the
importance of a patient-centred adherence model and
strong community activism for ART care [10]. This
study describes outcomes for adults in Khayelitsha
up to 5 years on ART and temporal trends in these
outcomes over 7 years, utilizing linkages with the South
African vital registration system to correct mortality
estimates for increasing loss to follow-up (LTF) in
recent years.
Setting
The Khayelitsha HIV treatment programme was estab-
lishedin2000atthreepublicsector primarycareclinicsin
Khayelitsha township, home to an estimated 500000
people. Antenatal HIV prevalence was 22.0% in 2001 and
32.7% in 2007 [11]. ART was ﬁrst provided through a
pilot demonstration project in May 2001, with modest
capacitytoprovidetherapyfor180adults[12].Bytheend
of 2007, the service had cumulatively enrolled over 7000
treatment-naive adults onto ARTand was operating as a
routine government service.
Adult patients are eligible for ART if their CD4 cell
count drops below 200cells/ml or if they have a WHO
stage IV condition other than extrapulmonary tubercu-
losis. The initial regimen was zidovudine (ZDV) and
lamivudine (3TC) together with nevirapine (NVP) or
efavirenz (EFV). Stavudine (d4T) replaced ZDV in the
standard ﬁrst-line regimen in late 2003 in order to align
with the South African national guidelines, which were
implemented in April 2004 [13]. Viral load (NucliSens
EasyQ HIV-1 assay; bioMe ´rieux, Boxtel, The Nether-
lands)andCD4cellcount(single-platformpanleucogat-
ing method) [14] testing are provided 6-monthly
after starting ART. Serum alanine aminotransferase and
haemoglobinaremonitoredforpatientsonNVPandZDV,
respectively. Guidelines make provision for a second-line
regimen (ZDV, didanosine and lopinavir/ritonavir) to be
started after virological failure is conﬁrmed (two conse-
cutive viral load results  5000copies/ml, in spite of
enhanced adherence promotion after the ﬁrst elevated
result).
The major sources of referral to the service arefrom acute
care and tuberculosis services in the subdistrict. Nurse-
based care has been central to this treatment programme
since inception with more than two-thirds of consul-
tations with nurses, and this model of care has continued
to evolve over time. The frequency and intensity of
clinical contact has decreased, with stable patients seen by
a nurse 2 or 3-monthly, and manyof the consultations for
long-term stable patients being integrated into group
sessions (‘clubs’). The adherence model remains patient-
centred but no longer includes routine home visits or a
signed patient contract. Pharmacist assistants now
dispense most drugs, and doctors see patients predomi-
nantly on the basis of internal referral of patients by
nurses.
Prevention of mother-to-child transmission (PMTCT)
services have been available since 1999, initially based on
short-course ZDV [15], and since late 2003, on both
short-course ZDV and peripartum NVP in women not
eligible for triple therapy [16]. Data on the type of
PMTCT received were not available for this analysis.
Methods
Data management and processing
Clinicians have used structured clinical records through-
out the periodof analysis, whicharecaptured on-site into
an electronic patient information system by dedicated
data capturers. All clinical care, record keeping and data
capture are part of routine patient management as per
provincial guidelines. Rule-based consistency checks
identify speciﬁc patients and data elements for review by
quality assurance staff.
This analysis includes all data on treatment-naive patients
(including those exposed only to PMTCT interventions)
of age 14 years and older, until the end of 2007. Mortality
and LTF estimates include patients enrolled until the
middle of 2007 in order to give all patients the
opportunity of meeting the LTF deﬁnition of 6 months
withoutaclinicvisit.Whenadjustinganalysesfor theyear
ofenrolment,theﬁrst2yearswerecombinedintoasingle
period due to the small numbers enrolled in these years
and similarity in patient proﬁle.
Civil identiﬁcation numbers, where available, were cross-
checked in the national death registry to conﬁrm or
ascertain dates of death for those with registered deaths. It
was not possible to differentiate deaths due to HIV from
deaths due to other causes. All data were anonymized
prior to being made available for analysis.
Follow-up laboratory results were considered as repre-
senting the nearest 6-monthly follow-up duration.
Baseline CD4 cell counts included measures from
564 AIDS 2010, Vol 24 No 4Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
12 months prior to 1-week posttreatment initiation. If
morethanonemeasurewasavailable,themeasureclosestto
baseline or 6-monthly duration was used. When compar-
ing viral loads on ﬁrst and second-line regimens, ﬁrst-line
viral loads were restricted to tests done prior to the
switching. Second-line viral loads were restricted to
measures that followed the initiation of second-line by at
least 3 months in order to exclude repeated baseline viral
loadsattheinitiationofsecond-line. Laboratoryoutcomes
arepresentedonlyforthosepatientsontreatmentinwhom
test results were available, and no assumption is made on
laboratory outcomes in those who missed a scheduled test
or who were lost to care at the time.
Analysis
Kaplan–Meier estimates of time to death and LTF (date
last seen) are described. A weighted Kaplan–Meier
approach was used to correct the mortality estimate for
those who were LTF but had died, by weighting those
patients who were LTF but for whom a deﬁnitive
outcome could be established from the death registry, to
represent all patients lost to follow-up [17]. Weights were
calculated separately by year and duration of follow-up.
Bootstrap conﬁdence intervals (CIs) for the weighted
Kaplan–Meier failure estimates were calculated by
sampling from the dataset with replacement 1000 times.
Patients who were known to have transferred to other
services were right censored at the date of transfer. Cox
proportional hazard models based on the same weighted
data were used to explore associations with early
(<3 months) and late mortality.
Virological responses were described as the proportion
below 400copies/ml at each year of follow-up for all
patients, and separately for patients on ﬁrst and second-
line regimens. Virological responses on ﬁrst and second-
line therapy were compared across all durations in a
logistic regression model clustered on individuals with
robust standard errors. CD4 cell responses were described
as median absolute value, change from baseline count and
change from previous count at each duration of follow-
up. This was repeated on a subset of patients who had
been continuously virologically suppressed until the CD4
cell count measure. Proportionswere compared using the
chi-squared test and medians using the rank sum test.
Time to conﬁrmed virological failure and time to the
initiation of second-line therapy were described as
standard Kaplan–Meier estimates, and associations with
virological failure were explored with a standard Cox
model. A population-averaged linear regression model
with an exchangeable correlation matrix was used to
explore associations with CD4 cell count responses in
each 6-month interval, limited to patients with continu-
ous virological suppression.
All analyses were conducted using Stata statistical
software, version 10.0 (Stata-Corp Inc., College Station,
Texas, USA). The analysis of routine cohort data and the
linkage to the national death registry were both approved
by the University of Cape Town Research Ethics
Committee.
Results
Annual enrolment increased from 80 treatment-naive
adult patients in 2001 to 2087 in 2006 (Table 1), with a
total of 7323 enrolled during the period under analysis.
Women constituted 68.2% of the cohort and were
younger at enrolment than men (median 31 vs. 36 years,
P<0.001). Overall, 3.7% of women initiated ARTwhile
pregnant and 11.1% had previously received PMTCT
interventions. Median baseline CD4 cell count increased
from 43 [interquartile range (IQR) 13–95]cells/mli n
2001/2002 to 131 (IQR 64–191)cells/ml in 2007. The
proportion with clinically advanced disease (AIDS as
deﬁnedbyWHOclinicalstageIV)[18,19]decreasedover
the same period from 54.5 to 28.9%. The proportion
initiatingARTwhilealreadyontreatmentfor tuberculosis
increased from 22.7 to 42.4%.
Civil identiﬁcation numbers were available for 57.0% of
all patients and 70.6% of patients enrolled in 2007
(Webtable 1). Cross-sectionally, 9.8% of patients enrolled
by the middle of 2007 (628/6402) had been LTF. Just
under half of those LTF had a civil identiﬁcation number
(46.7%),ofwhom32.8%hadaregistereddeathbeforethe
end of 2007. Patients lost in their ﬁrst year of treatment
(59.2%) were more likely to have died compared with
those lost thereafter (42.4 vs. 18.1%, P<0.001).
Inpatientswhosedeathswerereportedtotheservicesand
for whom a civil identiﬁcation number was available,
90.5% (172/190) were matched in the death registry,
whereas 99.9% (2941/2944) of patients known to be alive
and with valid civil identiﬁcation numbers were not
found in the registry, reﬂecting the sensitivity and
speciﬁcity of the data linkage.
Thecumulativeestimateofmortalitybasedonclinic-held
data was 15.5% (95% CI 13.1–18.3) at 5 years (Fig. 1a),
whereas the equivalent estimate of LTF was 23.4% (95%
CI 20.5–26.6). Combining LTF and mortality, 35.3%
(95%CI32.1–38.6)ofpatientswerelosttocareat5years.
LTF has occurred earlier with each successive year of
enrolment (Fig. 1b). The weighted estimates of mortality,
including patients LTF who could be matched in the
deathregistry,were9.9%(95%CI8.9–10.9),12.6%(95%
CI 11.5–13.8) and 20.9% (95% CI 17.9–24.3) at 1, 2 and
5 years, respectively (Fig. 1c). Incorporating the linkage
data, overall mortality has decreased over time (Fig. 1d).
Low baseline CD4 cell count, an AIDS diagnosis and a
low body weight were all strongly associated with
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mortality in the ﬁrst 3 months on ART (Table 2) and
remained associated, although attenuated, beyond 3
months. Older age (>50 years) was associated with
higher mortality after 3 months on ART. Year of ART
initiation was not associated with mortality after
adjustment for baseline characteristics.
For all patients combined, 87.6, 88.1 and 83.8% of those
who remained in care and received viral load tests were
virologically suppressed (<400copies/ml) at 1, 3 and
5 years, respectively (Table 3). Patients on second-line
ARTwere less likely to be virologically suppressed com-
pared with patients remaining on ﬁrst line at equivalent
durations on ART [odds ratio (OR) 0.51, 95% CI 0.26–
1.01], although 22 out of 29 (75.9%) patients on second-
line ARTat 5 years were virologically suppressed.
Patients who remained virologically suppressed through-
out follow-up had gained a median of 474 (IQR 341–
660)CD4cells/ml by 5 years and continued to gain a
medianof22cells/mlper6-monthperiodbetween4and5
years on ART (Table 3). Additional factors independently
associated with CD4 cell count gain (Table 4) were female
sex, younger age and measures of disease advancement at
ART initiation (AIDS, tuberculosis and low CD4 cell
count). At 5 years on ART, 3.7, 11.9 and 25.7% of
virologicallysuppressedpatientshadCD4countvaluesless
than 200, 200–349 and 350–499cells/ml, respectively.
By5years,14.0%(95%CI11.9–16.4)ofpatientshadmet
the guideline deﬁnition of conﬁrmed virological failure
(Fig. 2) and 12.2% (95% CI 10.1–14.8) had started
second-line therapy. Seventy-four percent of those
starting second-line therapy formally met the guideline
deﬁnition and started second line a median 5.3 (IQR
2.2–11.2) months after the date of the second raised viral
load. The remaining patients were started on second-line
therapy with one of the raised values being between 400
and 5000copies/ml or without a conﬁrmatory viral
load test.
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Fig. 1. Cumulative estimates of mortality, loss to follow-up and loss to care. Kaplan–Meier estimates of reported mortality and
loss to follow-up (a), loss to follow-up by year of initiation (b), corrected mortality (c) and corrected mortality by year of initiation
(d). ART, antiretroviral therapy; CI, conﬁdence interval.  Loss to care includes both those who have died and those lost to follow-
up.   Vital status was ascertained for patients lost to follow-up from the national death registry if a civil identiﬁcation number was
available. These patients were weighted in this analysis to represent all patients lost to follow-up. Vertical bars represent 95% CIs.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ART interruptions, PMTCTexposure, low initial CD4
cell count and the use of NVP (especially concomitantly
with treatment for tuberculosis) were all independently
associated with virological failure (Table 5).
Discussion
Our analysis demonstrates that ART beneﬁts, in a poorly
resourced primary care setting, are durable, with almost
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Table 2. Characteristics at the start of antiretroviral treatment associated with mortality in multivariate weighted Cox proportional hazard
models.
First 3 months on ART
a Beyond 3 months on ART
b
AHR 95% CI P AHR 95% CI P
Age  50 years 1.2 0.7–2.3 0.523 2.3 1.4–3.6 <0.001
Male sex 1.2 0.9–1.6 0.160 1.3 1.0–1.7 0.071
CD4 cell count category (cells/ml) <0.001 0.003
0–50 3.9 2.3–6.6 1.8 1.2–2.6
50–149 1.9 1.2–3.3 1.2 0.8–1.7
150–249 (ref.) 1.0 – 1.0 –
AIDS diagnosis when starting ART 1.8 1.3–2.4 <0.001 1.4 1.0–1.9 0.038
Baseline weight (per 10kg) 0.6 0.5–0.6 <0.001 0.8 0.7–0.9 <0.001
Was on TB treatment when starting ART 1.1 0.8–1.4 0.509 0.7 0.5–1.0 0.071
Year of starting ART 0.275 0.941
2001/2002 1.3 0.7–2.5 1.2 0.3–5.1
2003 1.2 0.6–2.1 1.2 0.3–5.5
2004 0.7 0.4–1.3 1.4 0.3–6.2
2005 1.0 0.6–1.7 1.2 0.3–5.0
2006 1.0 0.6–1.7 1.1 0.3–4.7
2007 (ref.) 1.0 – 1.0 –
AHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, conﬁdence interval; TB, tuberculosis.
a5346 observations, weighted n¼5631.
b4833 observations, weighted n¼4931.
Table 3. Viral load and CD4 cell count responses for up to 5 years on antiretroviral therapy.
1 year 2 years 3 years 4 years 5 years
Viral load
Combined
Total in care 4512 2561 1235 458 191
Tested (%) 3932 (87.1) 2198 (85.8) 983 (79.6) 351 (76.6) 148 (77.5)
Suppressed (%)
[<400copies/ml]
3446 (87.6) 1905 (86.7) 866 (88.1) 311 (88.6) 124 (83.8)
First line
Total in care (%) 4505 (99.8) 2506 (97.9) 1147 (92.9) 405 (88.4) 155 (81.2)
Tested (%) 3890 (86.3) 2127 (84.9) 914 (79.7) 310 (76.5) 119 (76.8)
Suppressed (%)
[<400copies/ml]
3407 (87.6) 1851 (87.0) 812 (88.8) 282 (91.0) 102 (85.7)
Second line
Total in care (%) 7 (0.2) 55 (2.1) 88 (7.1) 53 (11.6) 36 (18.8)
Tested (%) 5 (71.4) 47 (85.5) 63 (71.6) 41 (77.4) 29 (80.6)
Suppressed (%)
[<400copies/ml]
4 (80.0) 31 (66.0) 50 (79.4) 29 (70.7) 22 (75.9)
CD4 cell count
All patients
Total in care 4512 2561 1235 458 191
Tests available 3823 2108 931 341 127
CD4 cell count, median,
cells/ml (IQR)
297 (209–397) 383 (276–515) 425.5 (309.5–581) 486 (346.5–669) 512 (353–689)
Change from baseline,
median (IQR)
192 (116–282) 282 (180–406) 341 (224–488) 413 (263–580) 442 (266–615)
Change over 6 months,
median (IQR)
51 ( 7 to 111) 43 ( 18 to 111) 24.5 ( 55 to 99.5) 20.5 ( 54.5 to 124.5) 6 ( 85 to 116)
Patients with continuous viral load suppression documented
Tests available 3380 1847 820 307 109
CD4 cell count, median,
cells/ml (IQR)
304 (218–404) 398 (299–531) 459.5 (341.5–601) 511 (391–714) 542 (393–725)
Change from baseline,
median (IQR)
198 (124–288) 300 (203–420) 371 (251–509) 441 (317–629) 474 (340.5–659.5)
Change over 6 months,
median (IQR)
55 (2–116) 49 ( 11 to 117) 34 ( 44 to 105) 32.5 ( 51 to 141) 22 ( 78 to 147)
IQR, interquartile range.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
80% of patients remaining alive at 5 years, of whom more
than 80% of those tested were virologically suppressed.
Improvements in CD4 cell count and clinical stage at
ART initiation were translated in absolute terms into
improved survival since 2004. After adjustment for these
measures, we found that the rapid scale-up in patient
numbershasnot resulted in increasedmortality.Although
the link between improved access to care and reduced
early mortality has been previously reported in the
broader provincial programme of which the Khayelitsha
cohort is a part [7], the current analysiswas able to correct
for possible underascertainment of mortality.
The relatively high proportion of patients who have
remained virologically suppressed for up to 5 years on
treatment is reassuring. Nevertheless, almost one in ﬁve
patients reaching 5 years are on a second-line regimen in
spiteofthedelaysinswitchingtosecondline,suggestingthat
a substantial numberofpatientsare goingtoneed toaccess
second-line therapy as programmes mature. Predictors of
both virological failure and CD4 cell count gain
conditioned on continuous virological suppression are
rarely reported from scale-up settings. The association
betweenvirological failure and PMTCTexposure, in spite
ofthelikelymisclassiﬁcationofsomenon-NVPexposures,
adds to concerns that NVP-based PMTCT may compro-
mise future ART effectiveness [20,21]. The 1.6-fold
increased risk of virological failure following each treat-
ment interruption is also of concern, especially given the
highproportionofpatientswhodevelopserioustoxicityon
the current ﬁrst-line regimens in use, which often
necessitatestreatmentinterruption[22],andthatthemajo-
rityofinterruptionsinpatientslosttofollow-upwillnotbe
staggered to cover the longer half-life of non-nucleoside
reverse transcriptase inhibitors (NNRTIs) [23,24].
Patients in this cohort who remained virologically
suppressed continued to restore CD4 cells throughout
follow-up, with the rate of increase slowing as CD4 cell
counts reached the normal range. This ﬁnding is similar
to the equivalent subgroups of patients in recent analyses
of European and North American cohorts [25,26] but
differs from a collaborative analysis from resource-limited
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Table 4. Multivariate associations with 6-monthly CD4 cell count changes.
CD4 cell count changes
a over 6 months
Coefﬁcient
b 95% CI P
Male sex  14.3  17.1 to  11.5 <0.001
AIDS diagnosis at the start of ART 3.0 0.4–5.7 0.026
Had TB at the start of ART 4.7 1.8–7.6 0.002
Age at the start of ART (years) 0.107
16–24 (ref) 0.0 –
25–49  4.5  9.1 to 0.1
 50  7.4  15.4 to 0.6
CD4 cell count at the start of ART (cells/ml) <0.001
0–50 13.2 9.7–16.7
50–149 2.2  1.1 to 5.5
150–249 (ref.) 0.0 –
Duration of ART (months) <0.001
6 122.7 117.6–127.9
12–30 25.2 20.5–29.9
 30 (ref.) 0.0
Constant 33.7 27.6–39.7
ART, antiretroviral therapy; CI, conﬁdence interval; TB, tuberculosis.
aCD4cellcountchangesarechangeforeach6-monthlyintervalinpatientswhocontinuouslyhadviralloadsbelow400copies/mlupuntilthetime
of the second CD4 cell count measurement. Population-averaged linear regression model with an exchangeable correlation matrix, clustered on
individual patient. Thirteen thousand and forty-ﬁve observations are reported in 4314 patients.
bAdjusted for other variables.
Fig. 2. Time to virological failure and starting second-line
therapy.  Virological failure deﬁned as two consecutive viral
loadsabove5000copies/ml,atthetimeofthesecondelevated
value. ART, antiretroviral therapy; CI, conﬁdence interval.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
settings, which was not conditioned on viral load
suppression [27]. The negative associations between
CD4 cell count response and older age and male sex have
also previously been described [27]. In total, after 5 years,
41.3% of virologically suppressed patients had a CD4 cell
count below 500cells/ml compared with 35.8% in a
comparable study in Switzerland [28]. This difference is
most likely the result of the lower baseline CD4 cell
counts of patients in Khayelitsha and highlights how
advanced disease at enrolment results in more time spent
in CD4 cell count strata that carry substantial morbidity
and mortality [29].
It is well established that immunological measures are
poorlypredictiveofvirologicalfailure[30–33].Inspiteof
the controversies around the utility of viral load
monitoring in this setting [34,35], there is extensive
pressure for the more widespread availability of viral load
monitoring [36]. The current study is one of thevery few
in southern Africa to report on the systematic use of viral
load testing to identify treatment failure. Applied in a
context of rapid scale-up, the South African guidelines
still result in an average delay of many months between
the ﬁrst evidence of failure and subsequent switching.
This is the result of the time taken to conﬁrm the failure,
the pressures on service providers due to increasing
patient numbers and a reluctance on the part of clinicians
to commit patients to second-line therapy before
adherence issues have been exhaustively addressed.
It is unknown whether the delays in switching therapy in
viraemic patients as described in our study compromise
theeffectivenessofsubsequentregimensorwhether there
would be additional consequences of leaving patients on
their ﬁrst-line regimen until they fail immunologically.
Two recent African studies [37,38] reported genotypic
resistance data at the time of failure of ﬁrst-line ART.
As expected, both studies reported widespread resistance
to 3TC and NNRTIs. The Malawian study, in which
viral load monitoring is not available, reported a high
prevalence of thymidine analogue mutations and the
K65R mutation, but the South African study, in which
viral load monitoring is available, reported a much
lower prevalence of these mutations, suggesting that
virological monitoring will better preserve future
treatment options. With increasing numbers of patients
on second-line regimens, however, some of whom are
already failing second line, pressure for a third-line
regimen in resource-limited settings is emerging and
thereismoreconcern from clinicians aboutswitching too
late than too early.
Manyof those who have failed virologically and switched
to second-line therapy may have had suboptimal
adherence to their ﬁrst-line regimens and may be less
adherent than those who have remained on ﬁrst line.
This, in addition to the higher pill burden and more
complex dosing intervals of the available second-line
regimen, could explain the lower proportion of patients
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Table 5. Multivariate associations with conﬁrmed virological failure.
Virological failure
a
AHR 95% CI P
Male sex 1.0 0.8–1.3 0.977
Exposed to PMTCT prior to ART 1.5 1.1–2.0 0.024
Interruptions to ART (per interruption  7 days) 1.6 1.1–2.2 0.012
Age at the start of ART (years) <0.001
16–24 2.0 1.5–2.7
25–49 (ref.) 1.0 –
 50 0.9 0.5–1.7
CD4 cell count at the start of ART (cells/ml) 0.009
0–50 1.7 1.2–2.3
50–149 1.4 1.0–1.9
150–249 (ref.) 1.0 –
NNRTI used and TB status at the start of ART 0.002
EFV, no TB (ref.) 1.0 –
EFV, TB 1.3 0.9–1.9
NVP, no TB 1.5 1.1–2.1
NVP, TB 2.5 1.6–4.1
Year of ART initiation <0.001
2001/2002 2.1 1.4–3.0
2003 1.3 0.8–2.0
2004 0.9 0.7–1.3
2005 (ref) 1.0 –
2006 1.1 0.8–1.6
2007 0.7 0.2–1.8
AHR, adjusted hazard ratio; ART, antiretroviral therapy; CI, conﬁdence interval; EFV, efavirenz; NNRTI, non-nucleoside reverse transcriptase
inhibitor; NVP, nevirapine; PMTCT, prevention of mother-to-child transmission of HIV; TB, tuberculosis.
aVirological failure deﬁned as two consecutive viral loads of at least 5000copies/ml; n¼5743, Cox proportional hazards model.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
onsecond-linetherapywhowerevirologicallysuppressed
at each duration of follow-up.
OurﬁndingthatLTFisincreasingwith calendar timeisin
line with previous studies from resource-limited settings
[7,39], which we ascribe to rapidly increasing patient
numbers and resultant pressure under which services are
operating, and the declining ability of services to actively
trace patients who miss appointments.
A number of tracing studies [40–42] done in southern
Africa have demonstrated that upwards of a quarter of
patients LTF have died. Our analysis conﬁrms high
mortality in those lost to follow-up (33%). We also found
that the probability of death amongst those LTF is related
to the duration on ART prior to being lost. In order
to understand the long-term effectiveness of ART in
southern Africa, it will be necessary to establish well
supported sentinel cohorts in which ascertainment of
both laboratory and vital status outcomes is prioritized.
Initial positive reports of patient outcomes on ART in
resource-poor settings were interpreted by many as
demonstration projects, made possible by the investment
of additional resources that might not be sustained over
time and when scaled up. Khayelitsha is, however, one of
the most difﬁcult areas in the Western Cape Province in
which to provide health services due to chronic under-
resourcing and an enormous burden of infectious and
noncommunicable disease. The Khayelitsha ART service
has been predominantly staffed and run by government
health services for the past few years and has faced the
same stresses, understafﬁng and crises faced by the health
services in the area in general. When compared with
routine reporting across the entire province [7], or other
cohort studies in the province [43], Khayelitsha is an
averagely performing subdistrict. It is, thus, likely that
our ﬁndings are generalizable to other low and middle-
income countries, but aspects may not apply to
programmes without virological monitoring. In the ﬁrst
groupof patientsaccessing ART inBotswana followedup
to 5 years [8], cumulative mortality and LTF at 5 years
were 21.8 and 21.0% compared with 15.5 and 23.4% in
our study prior to incorporating death registry data.
Available viral load suppression measures in the Botswana
studywerecomparableorhigher thaninour studyateach
duration on ART. In a Senegalese cohort, cumulative
mortality at 5 years was 24.6% in a cohort with very low
reported LTF [44].
This study has a numberof limitations. First, although the
level of ascertainment of deaths through data-linkage
with national vital statistics may be an improvement on
what is feasible in many parts of southern Africa, the
sensitivity of the record-linkage was only 90%, indicating
residual underascertainment of a small proportion of
deaths. Although we do not consider that there is any
systematic bias introduced by patients who do and do not
have recorded civil identiﬁcation numbers, the lower
availability of this linkage ﬁeld for patients starting ART
intheﬁrstfewyearsofthecohortcouldhaveintroduceda
bias.Second,laboratoryoutcomesarelimitedtomeasures
that were available, and patients without tests available or
who were alive but no longer in care might have altered
these ﬁndings had it been possible to test them. The lack
of detailed exposure data impeded some of the
explorations such as the association between PMTCT
interventions and subsequent virological failure on
HAART, in which the inclusion of NVP in the PMTCT
intervention was not known. Finally, the absence of
resistance data in patients who were failing virologically
limited our ability to explore the effect of delays in
switching therapy on future treatment options.
At a time when there is uncertainty about continued and
increaseddirectbilateralandmultilateralfundingofART-
speciﬁc interventions in countries with limited resources,
these ﬁndings provide considerable reassurance that the
beneﬁts of ART in these settings are sustained. Many of
the early innovations to support patient adherence have
endured the rapid scale-up in patient enrolment and are
today standard of care in Khayelitsha and beyond. The
scale-up has itself led to further health service develop-
ments such as task shifting to nurse-managed clinical care.
This study has demonstrated substantial and durable
clinical beneﬁts for those able to access the intervention
throughout a 7-year period.
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Webtable 1. Linkages to the death register in patients lost to follow-up.
2004 2005 2006 2007 Total
Patients starting ART by mid-2007
n 1735 1641 2087 939 6402
Patients with valid recorded civil identiﬁcation numbers
n (% of total) 689 (39.7%) 966 (58.9%) 1332 (63.8%) 663 (70.6%) 3650 (57.0%)
Patients lost to follow-up
Lost in ﬁrst year on ART - n (% of total lost) 33 (19.3%) 92 (48.9%) 204 (90.7%) 43 (100%) 372 (59.2%)
Lost between 1 and 5 years on ART - n (% of total lost) 138 (80.7%) 96 (51.1%) 21 (9.3%) 0 (0.0%) 256 (40.8%)
Total lost - n (% of total started) 171 (9.9%) 188 (11.5%) 225 (10.8%) 43 (4.6%) 628 (9.8%)
Patients lost to follow-up with civil ID numbers
Lost in ﬁrst year on ART - n (% of lost) 4 (12.1%) 48 (52.2%) 97 (47.5%) 28 (65.1%) 177 (47.6%)
Lost between 1 and 5 years on ART - n (% of lost) 51 (37.0%) 55 (57.3%) 9 (42.9%) 0 116 (45.3%)
Total - n (% of lost) 55 (32.2%) 103 (54.8%) 106 (47.1%) 28 (65.1%) 293 (46.7%)
Weights used in the corrected mortality estimates
For patients lost in ﬁrst year on ART 8.3 1.9 2.1 1.5
For patients lost from 1 to 3 years 2.9 1.7 2.3
For patients lost from 3 to 5 years 1.9
Deaths in patients lost to follow-up with ID numbers
Lost in ﬁrst year on ART - n (% of lost) 3 (75.0%) 19 (39.6%) 38 (39.2%) 15 (53.6%) 75 (42.4%)
Lost between 1 and 5 years on ART -n (% of lost) 6 (11.8%) 13 (23.6%) 1 (11.1%) 0 21 (18.1%)
Total - n (% of lost) 9 (16.4%) 32 (31.1%) 39 (36.8%) 15 (53.6%) 96 (32.8%)
ART, antiretroviral therapy; ID, identiﬁcation.